Literature DB >> 25656980

Risk factors of recurrence among 471 Chinese patients with Budd-Chiari syndrome.

Xiuyin Gao1, Er Gui2, Zhaojun Lu3, Xin Ning4, Maoheng Zu5, Peijin Zhang6, Guixiang Sun7.   

Abstract

BACKGROUND AND AIM: Budd-Chiari syndrome (BCS) is a rare form of vascular disease. There is limited literature available regarding the prognosis of this disease. The aim of this study was to characterize the cumulative recurrence rates and to investigate the risk factors of recurrence in Chinese patients with BCS.
METHODS: Four hundred and seventy-one patients were diagnosed as having BCS in the Affiliated Hospital of Xuzhou Medical College (Jiangsu, China) between January 2008 and December 2012. Follow-ups were conducted by phone calls or correspondence. Cumulative recurrence rates were assessed with the Kaplan-Meier curves. Independent risk factors of recurrence were calculated with the Cox's proportional hazards regression model.
RESULTS: Four hundred and twenty-five patients with BCS had complete follow-up data, in which 24 patients died, 98 patients had recurrence, with the median duration of follow-up being 19.3 months (range 3 to 61.4). The cumulative 1-, 2-, 3-, 4- and 5-year recurrence rates were 12%, 22%, 27%, 35% and 42%, respectively. Univariable and multivariable Cox's proportional hazards regression models showed that the risk factors of recurrence include: age ≤ 30 years (HR=2.261, 95% CI: 1.412-3.621), differentiated typology (hepatic vein type: HR=1.885, 95% CI: 1.045-3.402; combined type: HR=2.088, 95% CI: 1.233-3.536), elevated lactate dehydrogenase (LDH) levels (HR=1.125, 95% CI: 1.101-1.212) and the Child-Pugh class B/C (B: HR=1.758, 95% CI: 1.057-2.926; C: HR=2.626, 95% CI: 1.396-4.940).
CONCLUSIONS: Regardless of thrombophilia and haematological causes, exceptionally found in Chinese patients, the 5-year recurrence rate of BCS was as high as 42%. Age ≤ 30 years, hepatic vein type, combined type, increased LDH levels and the Child-Pugh class B/C were independent predictors of BCS recurrence.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25656980     DOI: 10.1016/j.clinre.2014.12.010

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  4 in total

1.  Endovascular treatment for hepatic vein-type Budd-Chiari syndrome: effectiveness and long-term outcome.

Authors:  Zhong-Ke Chen; Jing Fan; Chi Cao; Yu Li
Journal:  Radiol Med       Date:  2018-05-31       Impact factor: 3.469

2.  Redefining Budd-Chiari syndrome: A systematic review.

Authors:  Naomi Shin; Young H Kim; Hao Xu; Hai-Bin Shi; Qing-Qiao Zhang; Jean Paul Colon Pons; Ducksoo Kim; Yi Xu; Fei-Yun Wu; Samuel Han; Byung-Boong Lee; Lin-Sun Li
Journal:  World J Hepatol       Date:  2016-06-08

3.  Risk factors for and causes and treatment of recurrence of inferior vena cava type of Budd-Chiari syndrome after stenting in China: A retrospective analysis of a large cohort.

Authors:  Wen-Dong Li; Hui-Ying Yu; Ai-Min Qian; Jian-Jie Rong; Ye-Qing Zhang; Xiao-Qiang Li
Journal:  Eur Radiol       Date:  2016-07-07       Impact factor: 5.315

Review 4.  An Update on the Management of Budd-Chiari Syndrome.

Authors:  A Sharma; S N Keshava; A Eapen; E Elias; C E Eapen
Journal:  Dig Dis Sci       Date:  2020-07-20       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.